ASCO Provides Input on CMMI's
ASCO has been working in parallel with various other institutions to generate a patient-centered oncology payment reform model.
Balancing Drug Breakthroughs with Rising Drug Costs
Hepatitis C and the price of Sovaldi were, understandably, the main focus of aconversation on rising prescription drug prices at the America’s Health Insurance Plans’ National Conferences on Medicare and Medicaid, and Dual Eligibles Summit in Washington, DC.
AHIMA’s Information Governance Framework Addresses Current Healthcare Challenges
A new information governance framework of 8 principles from the American Health Information Management Association aims to help meet the patient care, safety, and operational goals of healthcare organizations.
Ariad's Investigational NSCLC Drug: Breakthrough by FDA
The molecule is being evaluated in crizotinib-resistant ALK-positive NSCLC patients. The results from the phase 1/2 trial with AP26113 were presented at the 2014 European Cancer Congress.
Merck's HPV Vaccine Effective Against 9 Subtypes
The study, conducted in Austria, evaluated the potency of the 9-valent vaccine in preventing the development of cervical precancer in women infected with HPV.
New Receptor Target for Glioblastoma Multiforme Holds Promise
A review published in Neuro-Oncology provides insight into some of the molecules being developed to target IL13Rα2 in brain tumors.
Avoid Unnecessary Pap Tests: Study Concludes
A study published in the American Journal of Preventive Medicine found that lack of awareness resulted in women over 65 and those who had undergone hysterectomy routinely undergoing a Pap test.
A Look at the Future of Medicaid and Rate Setting
At $531 billion, Medicaid is the second largest piece of healthcare spending and cannot be pushed off to be thought about another day, Cindy Mann, JD, CMS deputy administrator and director of the Center for Medicaid and CHIP Services, said at the America’s Health Insurance Plans’ National Conferences on Medicare and Medicaid and Dual Eligibles Summit.
In The Literature: NSAID/Statin Influence on PSA in High-Risk Prostate Cancer Patients
The study, published in Cancer Epidemiology, Biomarkers & Prevention, evaluated the influence of NSAIDs and statins on PSA levels in men with a high prostate cancer risk.
Open Payments Website Launches, Reveals $3.5 Billion in Payments
The first round of Open Payments data, known as the Physician Payments Sunshine Act, were made public Tuesday and revealed 4.4 million payments valued at nearly $3.5 billion paid out to 546,000 individuals and almost 1346 teaching hospitals.
ASCO: Obesity a Risk Factor and Complication in Cancer
ASCO has called for raising awareness to control obesity, as it is not just a risk factor for developing diabetes but also for cancer.
ESMO 2014: New Regimen for BRAF-mutated Melanoma
Results from 2 phase 3 trials showed better response rates, progression-free survival, and overall survival when a BRAF inhibitor was combined with a MEK inhibitor, compared with a BRAF inhibitor alone.
Cigna Refers to NCCN Guidelines for Oncology Coverage Decisions
The Cigna-NCCN collaboration will benefit about 12.5 million members.
Reforming the Healthcare Delivery System
At the America’s Health Insurance Plans’ National Conference on Medicare and Medicaid and Dual Eligibles Summit in Washington, DC, Patrick Conway, deputy administrator for innovation and quality and chief medical officer for CMS, spoke on the future of delivery system reform.
ESMO 2014: Anamorelin Improves Quality of Life in Lung Cancer Patients
Phase 3 trial data from the ROMANA trials, presented at ESMO found that anamorelin improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia.
Fully Integrating Medicaid, Medicare Benefits May Not Reduce Spending
Plans designed specifically for disabled dual-eligible Medicare and Medicaid beneficiaries are not necessarily enough to reduce use of costly services, according to a new report from the Government Accountability Office.
JCO Study: MMA Did Not Influence Fee-For-Service Prescribing
The study by Kaiser Permanente found that prescription practices were not much influenced by the decrease in fee-for-service payments for outpatient chemotherapy, due the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
ESMO 2014: Nivolumab Promise in Melanoma
Results from the CheckMate-037 trial showed a significant increase in duration of response in patients with advanced melanoma administered nivolumab as second- or third-line therapy
Medicaid Enrollees Have Difficulty Getting Access to Care
Medicaid enrollment under the Affordable Care Act grew even in states that chose not to expand eligibility, making access to care a more pressing issue, according to a new report issued by HHS’ Office of the Inspector General.
Costs Can Go Up Fast When ER Is in Network but the Doctors Are Not
Even the most basic visits with emergency room physicians and other doctors called in to consult are increasingly leaving patients with hefty bills: More and more, doctors who work in emergency rooms are private contractors who are out of network or do not accept any insurance plans.
Employers May Find Savings From ACOs, Journal Reports
The accountable care organization, or ACO, can be a mechanism for employers to achieve healthcare savings, according to a just-published article in The American Journal of Accountable Care, the publication of The American Journal of Managed Care dedicated to healthcare reform.
Xalkori to Treat ROS1-Mutated Lung Cancer Patients?
Xalkori, currently approved for treating NSCLC with ALK rearrangements, reduced the tumor size in nearly 75% of the patients and also extended the remission period.
Without Teens in Cancer Trials, Cure Rates Won’t Improve
Fictional teens with cancer may be suddenly popular in film and TV, but they are hard to find in the one place where they are most needed: in clinical trials to find drugs to save their lives. A story in the new issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care, examines this problem.
Perjeta Improves Survival in HER2-Positive Breast Cancer Patients
The monoclonal antibody extended survival by nearly 16 months compared to those in the control cohort.
AJMC Review Offers Roadmap for Getting Paid in Molecular Diagnostics
Both Medicare and commercial insurers have raised the bar for molecular diagnostic companies, requiring them to show clinical utility to receive reimbursement for cellular tests designed to guide treatment in cancer, rheumatoid arthritis, and other diseases. An important new article in The American Journal of Managed Care reviews cases from a top Medicare contractor and outlines how to build the evidence to meet today’s standards.